San Francisco Sentry Investment Group’s Charles River Laboratories CRL Stock Holding History

San Francisco Sentry Investment Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-800	Closed	-$232K	–	695
2021 Q1	$232K	Hold	800	–	–	0.1%	203
2020 Q4	$200K	Hold	800	–	–	0.09%	202
2020 Q3	$181K	Hold	800	–	–	0.09%	199
2020 Q2	$139K	Hold	800	–	–	0.07%	218
2020 Q1	$101K	Hold	800	–	–	0.06%	214
2019 Q4	$122K	Sell	800 -1,800	-69%	-$249K	0.05%	269
2019 Q3	$344K	Hold	2,600	–	–	0.16%	142
2019 Q2	$369K	Hold	2,600	–	–	0.17%	137
2019 Q1	$378K	Buy	+2,600	New	+$342K	0.16%	141
2018 Q4	–	Sell	-29	Closed	-$4K	–	996
2018 Q3	$4K	Buy	+29	New	+$3.58K	﹤0.01%	685

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

San Francisco Sentry Investment Group's CRL Position: Q2 2021 in Review

San Francisco Sentry Investment Group sold out of Charles River Laboratories (CRL) in Q2 2021, closing a stake of 800 shares — an estimated $232K sold.

San Francisco Sentry Investment Group first reported a position in CRL in Q3 2018 and held it in 10 quarters. The position peaked at $378K in Q1 2019. 638 funds tracked by Wall St. Rank hold CRL as of Q2 2021.

San Francisco Sentry Investment Group reported no remaining Charles River Laboratories position as of Q2 2021 after selling out during the quarter.
San Francisco Sentry Investment Group sold 800 Charles River Laboratories shares in Q2 2021, an estimated $232K.
San Francisco Sentry Investment Group first reported a position in Charles River Laboratories in Q3 2018 and held it in 10 quarters.
San Francisco Sentry Investment Group's Charles River Laboratories position peaked at $378K in Q1 2019.
638 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2021.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2021, filed 2 Aug 2021.